Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancer

Bo Mi Ku(Samsung Medical Center), Myung‐Ju Ahn(Samsung Medical Center)
Oncotarget
June 28, 2017
Cited by 40


Related Papers